Skip to content

Beam Therapeutics BEAM Change in Other Assets

Change in Other Assets at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$13.18M+2,127%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$247K-61.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$1.84M+184%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$1.18M-107%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$18.85M+3,770%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.92M+102%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.42B+24.5%

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's change in other assets?
Beam Therapeutics (BEAM) reported change in other assets of $31.86M in Q1 2026.
How has Beam Therapeutics's change in other assets changed year-over-year?
Beam Therapeutics's change in other assets increased by 65122.4% year-over-year, from -$49K to $31.86M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.